3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Gliosarcoma
1
Glioblastoma
1
Interventions
venetoclax
26
ibrutinib
23
Rituximab
22
Cyclophosphamide
21
obinutuzumab
18
acalabrutinib
18
fludarabine phosphate
13
fludarabine
13
zanubrutinib
8
Bendamustine Hydrochloride
8
pirtobrutinib
7
Biopsy
7
Specimen Handling
6
Lenalidomide
6
CT-P10
6
Whole-Body Irradiation
5
Tacrolimus
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
duvelisib
3
Melphalan
3
Chlorambucil
3
Busulfan
3
idelalisib
2
daratumumab
2
Vincristine
2
Prednisone
2
Patient Reported Outcome Measures
2
Observation
2
Mesna
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Leukemia, Lymphocytic, Chronic, B-Cell
×
CLR1404
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled